Juvenile rheumatoid arthritis (JRA) is a common disorder of childhood that can be potentially devastating physically and psychologically. Over the last several decades, therapy for JRA has changed little. Therapy for advanced JRA is based on trial and error due to the lack of significant clinical trials for both old and new pharmaceutical agents. The following article is a brief overview of the disease and a review of the different treatment options available today with alook at some of the future developments in J RA research.
INTRODUCTION
I N 1897, THE concept ofJRA was theorized by George Fredrick Still after he recognized chronic synovitis in children. 1 It was not until 1976, when the first meeting of the American Rheumatism Association Conference on the Rheumatic Diseases of Childhood was convened, that the specialty of pediatric rheumatology was introduced. 2 Since that conference, few agents have gained FDA approval for the treatment of JRA, primarily due to the lack of prospective, controlled trials. There are several barriers of research into JRA. First, numerous studies have been published based on retrospective reviews, case reports, and extrapolation from experience in adult patients. Second, the lack ofconclusive research on traditional agents has made it even more difficult to study new drugs in meaningful head-to-head comparisons. Finally, the frequency of spontaneous remission for many children with JRA makes it difficult to determine the difference between study drug effect To whom correspondence should be addressed: Jennifer Baxter. PhannD. Columbus Regional Hospital. Pharmacy Department, 2400 and mere chance. It is for these reasons, and likely others, that pharmacists and other healthcare professionals have a large role in the care of JRA patients. They must be familiar with the large body of medical information that is available so they can understand and interpret the data and implement safe and effective therapy. In addition, they must be educators of patients, their families, and caregivers in order to provide them with the information they need to understand and take an active part in their therapy.
Starting with infiltration of polymorphonuclear leukocytes and an increase in joint fluid production, the synovium will begin to hypertrophy which can lead to articular cartilage erosion and finally erosion of the bony surfaces. 6 Affected joints display the symptoms of stiffness and decreased range of motion, pain, warmth, and erythema. 1 ,6 Systemic effects of JRA may also occur. These include iridocyclitis, rheumatoid nodules, fevers, rash, hepatosplenomegaly, lymphadenopathy, anemia, leukocytosis, and growth retardation. Different manifestations in the various subtypes of JRA have fostered the theory ofdifferent etiologies for each subtype. 6 Recent research has led to the theory of cytokines contributing in the pathogenesis of JRA. 4 ,8,9,10 Several additional theories for the etiology have been proposed, such as infectious, traumatic, environmental, genetic, and immunologic mechanisms resulting in an autoimmune disease. 1 ,4,S,6 Research findings have suggested a possible link between other autoimmune disorders such as juvenile diabetes and the absence of breast-feeding, which is thought to provide a protective effect. 1I ,12 Unfortunately, the results of these studies are conflicting. With increasing recognition ofthe function of cytokines in inflammatory disorders, and the unique features of the different subtypes of IRA, distinct mechanisms for each subtype are being theorized, Current research is heavily focused on cytokine imbalances, but a definitive cause of IRA is yet to be established.
DIAGNOSIS
The diagnosis of JRA in the United States is based on criteria developed by the American College of Rheumatology. These criteria include onset of disease with a 6 week or greater duration before 16 years of age, arthritis in one or more joints, or two or more of the following signs: limited range of motion, tenderness or pain on motion, and increased warmth of the joint. 6 Diagnosis of arthritis and the particular subtype is decided after 6 months of disease dura-tion. In addition, the diagnosis must involve the exclusion of other diseases such as serum sickness, septic arthritis, Lyme disease, rheumatic fever, spondlyarthropathy, systemic lupus erythematosis, osteomy6elitis, inflammatory bowel disease, leukemia or other neoplasm, sickle cell anemia, hemophilia, and Henoch-Schonlein purpura. 3 ,4,5,6 Patients may present with low grade fever, malaise, anorexia with concurrent weight loss, shortness of stature, morning stiffness, and pain upon joint movement, however, the latter two are not perceived as often as in the adult population. Because very young patients may be unable to communicate pain, other subtle signs of JRA may include a guarding of the joints, refusal to ambulate, and increased irritability.5,6
CLINICAL MANIFESTATIONS
There are three recognized subtypes of IRA: systemic, pauciarticular, and polyarticular onset. Systemic onset disease consists of arthritis and intermittent fever. Pauciarticular onset involves 4 joints or less, and polyarticular onset is defined as involving 5 or more joints. 6
The subtypes are differentiated primarily by the pattern of disease onset and chronic symptoms. Pauciarticular and polyarticular subtypes are further subdivided into subsets by serologic findings, pattern of onset, and clinical manifestations. 3 Systemic onset JRA is seen in approximately 10-20% of JRA patients. The age of onset varies, and there is a slight dominance of males in this subtype. Systemic onset is categorized by high fevers (39°C or higher) which may occur once or twice daily, normally in the morning and late afternoon to evening, and is associated with a prominent macular rash. The rash, which is usually apparent on the trunk, sometimes occurs on the palms, soles, axillae, and face of the patient and tends to migrate.1. 6 Fever and rash rarely persist longer than 6 months. Extraarticular manifestations are also commonly seen in systemic onset JRA. These may include anemia, hepatosplenomegaly, lymphadenopathy, pericarditis, myocarditis, and more rarely lesions on the valves, disseminated intravascular coagulation, renal papillary necrosis, diffuse interstitial pulmonary fibrosis, hematuria, proteinuria, and amyloidosis. 1.3.5. 6 Radiologic findings have been well described by a longitudinal study of disease progression in systemic onset JRA. Results of the study showed symmetrical swelling of the soft tissues early in the disease, followed by narrowing in the joint space itself, and subsequent erosion of the bone. The joints most commonly affected included the wrists, followed by the ankles, knees, and distal and proximal phalangeal joints in the hands. Frequently, findings also include osteopenia, followed by growth retardation and loss of cartilage. 13 Subsequent development of polyarticular arthritis can also be seen in a large proportion of systemic onset JRA patients.
Pauciarticular onset JRA is found in 40-50% of children with JRA. The strict definition of this subtype by the American College of Rheumatology says 4 or less joints are involved; however, this is not an exclusion for patients who might exhibit additional joint involvement. Patients with pauciarticulardisease are further categorized into early and late childhood onset subsets. The subset of ANA positive patients accounts for 30-40% of all patients with JRA. These individuals are primarily females, with age of onset within the first 5 years of life. The joints more commonly affected are the elbows, ankles, and knees. After 6 months, if no progression in disease is seen, 80% will not develop polyarthritis in the future. Since the risk of iridocyclitis is much higher in this subset of JRA (approximately 30%), the recommendation is to undergo quarterly ophthalmologic exams in order to decrease the risk ofcomplications if undiagnosed and untreated. 1, 7 The other subset of pauciarticular disease presents with a positive HLA B27 antigen which is associated with the development of sacroiliitus. The predominant characteristics of this class are male gender with onset after the eighth year, and possible family history of spondlyoarthropathies. This subset may experience considerably more pain; however, de-struction of the joint is less common. Joints affected are located in the lower extremity and include the hips, knees, feet, and ankles. 3 . 7
The incidence of polyarticular onset rheumatoid arthritis is estimated to be 35%.1 The manifestations of this subtype may include systemic complaints such as low grade fever, anorexia, anemia, slight hepatosplenomegaly, and short stature. 7 Polyarticular JRA is also broken into subsets by the presence or absence of rheumatoid factor. Rheumatoid factor positive JRA has been compared to that of adult rheumatoid arthritis and is characterized by a sudden onset in several joints after 8 years of age, the presence of rheumatoid nodules, and the rapid destruction of joints within 6 to 12 months. Rheumatoid factor negative polyarticular JRA is also associated with sudden onset, but the patients may be considerably younger. Patients in this subset usually avoid significant destruction of joints and have a good response to therapy. 1,3.7
LABORATORY EVALUATION
Serologic evaluation of JRA further divides the pauciarticular and polyarticular subtypes. In all patients, a biopsy of the affected synovial tissue reveals the presence of a significant number of polymorphonuclear leukocytes (10,000-lOO,OOO/mm 3 ) and a decreased level of glucose. 1 As previously mentioned, rheumatoid factor, antinuclear antibodies, and certain histocompatibility antigens such as HLA B27 may be found in subsets of patients with JRA. There are many serologic and other immunologic markers in this category which are being investigated to determine their specificity for predicting the development of the different subtypes of JRA.6.8.9.10
During periods of inflammation, several other general findings may include leukocytosis, thrombocytosis, and an increase in erythrocyte sedimentation rate and C-reactive protein. In patients with chronic disease duration, hypochromic normocytic anemia, and decreased albumin levels may be seen.1.5 At this time, laboratory data is used primarily to rule out other diseases such as septic arthritis and to obtain early evidence of subtype classification. I . 5 ,6
COMPLICATIONS
The most obvious complication of JRA is articular deformity resulting from continuous destructive inflammation and bony erosion. In addition, uveitis, if undiagnosed or treatment delayed, can progress to posterior synechia, band keratopathy, cataracts, secondary glaucoma, and blindness. I [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Juvenile rheumatoid arthritis is associated, more specifically, with iridocyclitis which is inflammation of the ciliary body and iris. 17 After articular deformity, uncontrolled iridocyclitis is associated with the most morbidity of any JRA complication. The overall incidence of iridocyclitis has been estimated between 2 and 21 %.17 A more recent study which may be the most representative sampling of the JRA population, has estimated that the incidence is actually 9.3%, suggesting that previous studies may have shown a higher incidence due to the presence of iridocyclitis upon initial diagnosis or referral to a pediatric rheumatology clinic. 16, 18 Iridocyclitis is seen predominately in females diagnosed with the early childhood pauciarticular subset who are positive for the ANA factor. 6 ,14,18-20 The onset of iridocyclitis may occur within 5 to 7 years after the initial diagnosis of arthritis; however, it can also occur significantly later during adulthoodP The signs and symptoms include red eyes, diminished vision, unequal pupils, headache, and ocular pain. I ,15,19 These signs mayor may not be present with the onset of disease, therefore, necessitating periodic slit lamp ophthalmologic exams. This is the only definitive way to diagnose iridocyclitis. The American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology have published a set of recommended guidelines for the periodic ophthalmologic eye exams taking into account each subtype and perceived risk for development of iridocyclitis.17 In general, slit lamp examinations should be performed quarterly in patients with pauciarticular onset and preferably biannually for all other patients with JRA.I,7,16 Early diagnosis and treatment of iridocyclitis are the only way to slow disease progression.
PROGNOSIS
The prognosis for patients with JRA has improved significantly from previous years. Increasing research into the etiology of JRA, better imaging techniques and diagnostic aids, specific care guidelines, and newer pharmacologic agents have led to an increased chance of slowing progression and reducing complications of this disease. Fortunately, erosion of bone is less commonly seen in childhood arthritis. Because ofthis, it is estimated that recovery without serious disability is seen in 70-90% of JRA patients. 6 ,7 The prognosis of patients with iridocyclitis is very good for 25%, moderately good for 50%, but they may need prolonged therapy, and poor in 25%. 6, 17, 20 The patients with the most severe disease may require surgery for cataracts and glaucoma. An estimated 15-40% of patients with iridocyclitis will eventually develop blindness. 17
TREATMENT
The treatment goal of JRA is to decrease inflammation in the affected joints and prevent deformity, all the while maintaining as normal a life as possible in the child. Because of the numerous factors involved in the disease, an interdisciplinary team made up of healthcare workers is recommended for complete care. This team should consist of the physician, pharmacist, physical and occupational therapists, social workers, and psychologist,5,6,7,2l,22
Education
Education is an integral part of JRA therapy. The patient and caregivers benefit from an indepth understanding of the disease process. They learn the importance of compliance with physical therapy and medication regimens in fending off disease progression. This way, patient involvement is believed to foster a better adherence to therapy. 6 
Health Assessment
Health-related quality of life assessment is important in chronic diseases, especially in childhood rheumatic disorders. Until recently, health assessment tools focused mainly upon disease activity to determine efficacy of therapy. 23 With respect to JRA, many more parameters are needed to determine the effectiveness of treatment. These include quality of life assessments encompassing functional ability, and the patient's assessment of their progress. Health-related outcome assessment tools are a valuable asset to clinical trials; however, the outcome-based trials in pediatric rheumatology have been inconclusive because of the placebo effect. Comparison between a study drug and standard therapy, usually consisting of NSAIDs, has been difficult. One theory to explain this discrepancy revolves around the lack of an adequate universal standardized health assessment tool taking into account quality of life variables. Because ofthis, several pediatric assessment tools have been revised to include consideration of these factors. After review of the different health assessment instruments available, an analysis has suggested that the Childhood Health Assessment Questionnaire (CHAQ), the Juvenile Arthritis Functional Assessment Report (JAFAR), and the Juvenile Arthritis Quality of Life Questionnaire (JAQQ) are appropriate and helpful in determining the value and progress of a particular therapy. 23 With the standardization ofdisease assessment, it is felt that clinical trials may be more objective in comparing outcomes and providing valid results. 24
Physical and Occupational Therapy
Even though many different pharmacologic agents exist today for the treatment of JRA, physical and occupational therapy remain the cornerstone of therapy. Only through continued use and range of motion exercises can the patient expect to ward off tendon. ligament. joint shortening or atrophy. and preserve function. 5 Lack of adherence to an individualized exercise program can significantly compromise a patient's therapy. Patients with JRA also commonly experience osteoporosis, and strength building exercises can help these patients retain bone and retard bone loss.22 Before any form of exercise/therapy is initiated, it is important to remember to make sure that the patient has adequate pain relief. 25
Physical therapists should be consulted to help develop an individualized program for the child. Although patients should be encouraged to engage in the normal everyday activities of childhood. they also need to recognize that certain sports may be more dangerous. Acceptable exercise includes swimming, biking, dancing, low impact aerobics, and other exercises which flex muscles and joints without increasing the risk of stress on the joints. 1 • 6 • 22 Prior to therapy, it is important to remember to provide adequate pain relief.
In addition to exercises, some children may need additional therapy which can include the use of heat and cold on the affected area to decrease swelling during times of active disease and decrease morning stiffness before school or other activities. Different types of splints and braces are also available to help rest the joint, and gently keep the joint stretched to prevent contractures of the muscle. Serial casting may be employed to aid in preventing deformities of the joint and surrounding muscles. 5 . 6 
• 22
Occupational therapy is required for those patients who have been affected to the point that activities of daily living are difficult. Therapy for maintaining independence is also crucial to the patient's psychological well-being. At any point in the disease state that a patient relapses and loses the ability to perform these functions, all efforts should be made to help regain the patient's independence as soon as possible. 22 Attempts should be made to keep the child from relying on crutches, walkers, canes, or wheelchairs. The caregiver should help the child remain adherent and provide creative ways to keep them involved in their therapy. This positive reinforcement could include a reward for a certain amount of time spent doing their exercises. 22 Finally, there are camps for children afflicted with rheumatic disorders. These can foster a sense of independence while providing a safe physical environment in which they can participate with other children. 25
Surgical Management
Several surgical procedures are available as adjuncts in the treatment of JRA. These are performed only as a last resort and do not affect the progression of the disease itself. Synovectomy and tenosynovectomy may be used to provide relief; however, there is no effect on the course of the disease itself. Synovectomy is performed to remove the inflamed synovial tissue from the joint and help prevent destruction and subsequent deformity. Indications for this procedure in pediatric patients include six months of resistant synovitis, swollen joints, persistent pain, decreased range of motion, and radiologic evidence of joint destruction. Surgery is controversial since many patients with JRA may spontaneously remit; however, joint destruction can cause significant, permanent deformity. Tenosynovectomy, which involves the excision of the tendon sheath, is indicated in children when the finger and thumb become locked through inflammation of the sheath. This is a fairly common finding in JRA (59%). As a last resort, replacement of an affected joint is possible, but is usually avoided until the child has reached the end of skeletal bone growth at approximately 18 years of age. 3 ,5
Pharmacologic Management
As previously mentioned, relatively few new pharmacologic developments since 1976 in JRA have been shown to slow disease progression. The advent of the class of disease modifying agents known as slow acting antirheumatic drugs (SAARDs), or disease modifying antirheumatic drugs (DMARDs), has made available more options for the treatment of those patients who do not respond to initial therapy.
Salicylates
Aspirin was the first agent used in the treatment of JRA. 5 Although it is known as an NSAID, it will be discussed separately. The mechanism of aspirin and the NSAID class involves inhibition of cyclo-oxygenase, thereby inhibiting the production of prostaglandins. In addition, phospholipase C, aggregation of neutrophils, and free radical generation are also inhibited. 22 This mechanism of action provides the anti-inflammatory properties ofthe agents.
The use of aspirin is still a frequent practice
The liquid formulation choline salicylate is safe and convenient for younger children who cannot swallow tablets.
for the treatment of JRA today because of its convenient forms of administration and inexpensiveness. There are differing recommendations for dosage of salicylates. The range recommended is to start from 70 mglkglday and titrate to response or to approximately 120 mglkglday,5 A weight-based recommendation was also described with patients weighing 25 kg or more to start at 50-70 mglkglday, and those weighing less than 25 kg to start at 70-100 mglkglday.7 The liquid formulation choline salicylate is safe and convenient for younger children who cannot swallow talr lets. 26 The most common side effects seen with therapy are gastritis and subsequentõ rexia. 2 . 27 The risk of gastritis can be greatly reduced by using enteric coated aspirin, dividing the total daily dose of aspirin into four doses to be given with milk or meals, and by adding agents such as antacids, H 2 blockers, or sucralfate. 2 ,6,26 Additional side effects seen with salicylate therapy may include behavioral changes and irritability.l,7 These may necessitate a decrease or discontinuation of therapy. Increases in liver transaminase levels are also commonly seen, but tend to decrease after therapy has been continued three months or more. 2 6--28 Salicylate toxicity may manifest as nausea, vomiting, and metabolic acidosis as evidenced by tachypnea. 7 The serum level correlating with this severe side effect is usually greater than 30 mg/dL,28 Rarely, nephropathy, peptic ulcer disease, urticaria, asthma, and disseminated intravascular coagulation may occur. 27 A discontinuation of therapy after chickenpox or other viral illness is necessary in order to avoid the possible onset of Reye' s syndrome. 1 ,7,27 As an adjunct in decreasing the risk of viral infection, the influenza and varicella vaccines can be administered. 7 An indication of the patient's adherence to the medication regimen or toxicity of the aspirin can be determined by obtaining a serum level at least 5 days after initiation of therapy or a subsequent dose adjustment. A serum level may be especially important when tapering a steroid due to increased clearance of salicylates with concurrent steroid therapy.2
NSAIDs
NSAIDs such as ibuprofen are gaining increased favor in the treatment of JRA due to the ability of twice a day dosing. Of the NSAID class, the agents approved for use in JRA are naproxen 15 mglkg/day in two doses, tolmetin 25 mglkg/day in four doses, and ibuprofen 35 mglkg/day in three to four doses. 3 ,6,27 A study with ibuprofen dosed in a range from 10-40 mglkg/day found that the average dose required for benefit was 25 mglkg/day, with the most frequent side effect being abdominal pain. 29 A suspension formulation is available for ibuprofen and naproxen, making them an attractive therapy for use in children and easier to titrate to response in younger children. 6 The side effect profile of these agents is similar to that of salicylates. Care must be taken to avoid gastric irritation, and frequent hemoccult test-ing is recommended. 2 As nephropathy and hepatoxicity may be side effects, it is important to maintain an adequate level of hydration in the patient and to obtain a urinalysis, BUN, creatinine, and liver transaminase levels at least quarterly. 6.27 It is estimated that one-third to one-half and as high as 70% of all patients treated with NSAIDs respond to therapy.2.6,30 It has also been observed that if one NSAID provides little efficacy, a second and third NSAID may be tried with some success, proving cross-tolerance may not be absolute within the class. 2 One study determined that a time period of at least 8 weeks should be given to determine the efficacy of these agents, and in some patients, 4 weeks may be required at the maximum dose to show evidence of response. 31 The duration of therapy with NSAIDs after disappearance of the disease may need to be continued for one to two years. 6 ,7
A new class of NSAIDs, the cycla-oxygenase 2 (COX-2) inhibitors has just been introduced to the market. Traditional NSAIDs inhibit both COX-l and COX-2. Inhibition of these enzymes prevents the formation of different prostaglandins. The inhibition ofCOX-2 is thought to be the main mechanism of NSAID anti-inflammatory activity, while the inhibition of COX-l is responsible for the inhibition of mucosal defense predisposing the patient to peptic ulcer disease. The major advantage of these agents is the decrease in the risk of mucosal injury over traditional NSAIDs. 32 The first COX-2 inhibitor to be approved was ceiecoxib (Celebrex®).33 It is approved for treatment of the signs and symptoms of adult rheumatoid arthritis and osteoarthritis. It has been shown to have similar incidence of ulcer occurrence compared to placebo and significantly lower incidence than comparator NSAIDs such as naproxen and diclofenac. The studies to date have been small and involved specific patient populations. Post-marketing surveillance and phase IV studies will be needed to determine the actual incidence of ulcers and the risk to the pediatric population. To date, no studies have been published involving celecoxib or other COX-2 inhibitors in IRA or other pediatric patient populations.
Glucocorticoids
Glucocorticoids have played an important part in the treatment of IRA. The mechanism of action is similar to that of NSAIDs, however, they inhibit processes higher in the cascade system of prostaglandin and cytokine production. Unfortunately, the broad inhibition of inflammation is also responsible for the significant side effect profile. Osteoporosis, avascular necrosis, growth retardation, secondary glaucoma, immunosuppression, and gastrointestinal ulceration preclude their use over a long period of time without extensive consideration. 7 The use of steroids today is reserved for resistant systemic manifestations of therapy, intra-articular administration into affected joints, and treatment of iridocyclitis. The dose ofprednisone for systemic manifestations is 0.1 mglkglday to 1.0 mglkglday (maximum 40 mg) given as a single dose, or 2 mglkglday divided into three doses. 6 . 27 Intra-articular therapy is done with triamcinolone and methylprednisolone but should be limited to one injection a month for a period of three months. 2 • 6 Topical steroid therapy, which may be supplemented with 2-4 mg of prednisone, is beneficial in the treatment of iridocyclitis but may exhibit significant side effects such as secondary glaucoma. 6 ,7 Gastrointestinal upset can be minimized by taking the medication with food in the morning and decreasing the dosing frequency to every other day. It is important to taper slowly when discontinuing therapy of duration longer than 5 days to avoid an exacerbation of arthritis. 2 ,27 The most recent benefit of steroid therapy has been seen with the use of pulse doses of 10-30 mglkglpulse administered on alternate days. A study in 19 children with disease refractory to traditional approaches was done involving pulse doses of 500 mg of intravenous hydrocortisone every 6 hours, versus single doses of methylprednisolone 30 mglkg. 34 The results showed a significant improvement in four pa-tients who attained remission. Several others are now receiving doses every 1 to 2 weeks to maintain effect, and all of the patients were able to decrease the dose and/or frequency of oral steroid doses. Several patients crossed over to another steroid therapy group if they had suboptimal response to their original treatment, and they typically then experienced control. A few cases of hypotension and hypertension were reported with hydrocortisone therapy. Laboratory values obtained during this period showed that the study drugs had no significant effect on white blood cells, but patients on hydrocortisone had a significantly greater decrease in sodium excretion on each day of therapy than those treated with methylprednisolone. After the study, no hypertension or cushingoid side effects developed. The conclusion of the study was that large pulse doses of intravenous steroids are safe and may provide benefit in the treatment of severe patients with refractory IRA.
Gold Compounds
Gold compounds historically were considered second-line therapy in IRA. The mechanism of action is unknown and can only be theorized to act at multiple sites in the immune system. 27 The use of parenteral gold is fairly uncommon today. The adverse effects, expense, and lack of clinical trials make it difficult to support its use. Adverse events of gold compound include dermatitis, gastrointestinal problems, nephritis with hematuria and proteinuria, and bone marrow suppression, specifically leukopenia and thrombocytopenia. 2 ,6,3o Rash and mouth ulcers may also be seen. 7 • 27 The dose of parenteral gold is 0.25 mglkg (or 5 mg) as a test dose, then increased by 25%-50% the following week. 2 • 27 After this, the dose should be increased at weekly intervals to 0.5-1 mglkg with a maximum of 50 mg per dose. 2 It is important to remember to adjust for weight gain. Upon a cumu!ative dose of 500-1000 mg, the patient should be reassessed. If the patient shows significant response, decreasing injections to monthly intervals may be possible. Response time is usually 6 to 12 weeks, and optimum results are seen within 3 to 12 months. 27 Urinalysis, platelet counts, and complete blood counts with differential should be drawn prior to each dose, and a chemistry panel should be drawn every 6 weeks. 2 ,6,27 The number of children responding to parenteral gold therapy has been estimated at 50%, while 25% of these children may discontinue therapy due to adverse side effects. 3o The lack of controlled trials with parenteral therapy has made an evaluation of the benefit of therapy difficult. Contraindications to the initiation or continuation of therapy include severe leukopenia, neutropenia, proteinuria, or exfoliative dermatitis. Insignificant hematuria or proteinuria may require only a brief reprieve of one month's duration and reinstatement of therapy at a lower dose. 27 Significantly more trials have been done with oral gold (auranofin) therapy. The dose used is 0.15 mglkglday with a maximum of 9 mg. 6 Other than dose-related diarrhea, oral gold is fairly well tolerated. The labs necessary for monitoring toxicity include a blood count and urinalysis once a week for 2 weeks, then monthly, and a chemistry panel every 6 weeks. 27 It is important to realize that the effect of the oral formulation may take 6 months or longer to be seen. 7 Although many studies have been done with oral gold in the treatment of JRA, the results have been controversial. Recent evaluation of the clinical trials unfortunately suggests oral gold may be relatively ineffective. In an early retrospective study, 51 patients showed a large proportion of responders to oral gold therapy. 35 A trend was also noted in that the greatest response was observed in the polyarticular group. An open label noncontrolled trial of oral gold was performed in 21 patients several years later. 36 ,21 The results of this trial demonstrated that approximately 50% had clinically significant improvement, and a higher dose was attributed to a better response. The two dosages used in the trial were 0.1 mglkglday and 0.15 mglkglday. Adverse effects were similar to those in previous studies. A placebo-controlled, double-blind trial between the U.S. and the U.S.S.R. was performed with auranofin. 37 Two hundred and thirty-one children were enrolled in the 6-month trial, and results showed that both the placebo and auranofin groups experienced a significant response to therapy. In addition, a comparison between the two groups showed no statistically significant differences, however, a trend of greater response was seen in the auranofin group. Another trend was that those patients with a shorter period of disease onset before treatment had a slightly better response. This trial has been the best attempt to date in defining the efficacy of oral gold. Most recently, outcomes were analyzed from a 5-year open extension trial. 38 The results showed that of 88 children, only 5 completed all 5 years. The number of patients in remission at their final visit was 17%. The final conclusions were that only a small percentage of patients benefit from this therapy, therefore confirming previous conclusions from the cooperative trial between the U.S. and the U.S.S.R.
D-Penicillamine
Penicillamine is hypothesized to be beneficial in JRA by increasing the removal of circulating immune complexes. 2 Therapy is initiated at 3 mglkglday on an empty stomach and increased over several months to a single daily dose of 10 mglkglday with a maximum daily dose of 750 mg. 2 ,6 Time to response is 6 months. Bone marrow suppression, thrombocytopenia, and renal toxicity as evidenced by proteinuria are three of the more serious side effects. Besides these, drug-induced lupus, loss of taste, vomiting, nausea, rash, dermatitis, and pruritis may be seen. 2 ,6,27 Several trials have been done to determine the effects of penicillamine, many results of which are inconclusive and controversial. A double-blind placebo-controlled study with penicillamine was done in 70 children in doses of 5 mglkglday versus placebo for 6 months. 39 The dose was gradually increased to 10 mglkglday. Significant effects observed were a decrease in pain and number of stiff joints. Side effects experienced included thrombocytopenia, rash, vomiting, and abdominal pain. Adverse effects caused only two patients to withdraw from the study. The U.S.-U.S.S.R. study involving penicillamine used the same doses, and the results of that study conflicted with the prior study in that relatively little benefit was seen with the use of penicillamine over placebo. An explanation for the difference in findings is that the U.S.-U.S.S.R. study was more controlled regarding concurrent medication regimens. Conclusions from these two studies lend themselves to much interpretation. It appears today, however, that the use of penicillamine has decreased as newer, more effective drugs such as methotrexate have been approved. When penicillamine is prescribed, complete blood The use of penicillamine has decreased as newer, more effective drugs such as methotrexate have been approved.
counts and urinalysis should be drawn weekly for a month and every 3 to 4 weeks thereafter as well as a chemistry panel every 6 weeks, with a creatine phosphokinase done biannually.2,27
Hydroxychloroquine
Hydroxychloroquine, an antimalarial agent, has also been advocated as an effective JRA treatment, but its mechanism of action is unknown. 7 The U.S.-U.S.S.R study evaluated hydroxychloroquine at a dose of 6 mglkg/day and found the difference in the treatment group versus placebo to be negligible. 40 In addition, the toxicity of this drug during long-term use (greater than 2 to 3 years) makes it a less desirable therapeutic option. 37 These toxicities are attributed to the accumulation ofthe drug in the pigmented tissue of the eye and may manifest as corneal deposits, color blindness, and macular retinitis. 7 . 27 Lower doses of 5 mglkg/day can also help decrease the risk of these effects. 3o Other, less frequent side effects observed with hydroxychloroquine are dermatitis, gastrointestinal problems, and cytopenia. 3o It is advisable to avoid this medication in younger JRA patients who might not be able to cooperate and complete a proper vision examination. 27 The use of hydroxychloroquine in doses of 5-7 mglkg/day with a maximum of 300-400 mg/day may be tried in refractory patients; however, if no response is seen within 6 months, hydroxychloroquine should be discontinued. 2 . 6
Sulfasalazine
The use of sulfasalazine in JRA is controver-sia1. 5 Sulfasalazine is a combination of 5-aminosalacylic acid and sulfapyridine. The first moiety is not significantly absorbed and stays in the intestine, thus the mechanism of action ofthe drug is attributed to sulfapyridine. 2 .41 Sulfasalazine has been shown to provide relief in patients with JRA who have not responded to first-line therapy, however, it is at the risk of significant toxicity and side effects. 27 Side effects of sulfasalazine include diarrhea, mood changes, hepatotoxicity, male infertility, gastrointestinal irritation, bone marrow suppression, ulcers of the mucosa, exfoliative dermatitis, and Stevens-Johnson syndrome. 6 ,3o One study had similar results regarding efficacy of this agent, however, the results were broken down by subtype. 42 Their study of 51 children showed a response in only 12 patients at a dose of 40 mglkg/day. The characteristics of these 12 included predominately male gender, with later onset (greater than 9 years of age), HLA B27 antigen positive, and pauciarticular arthritis. The conclusion of the study was that sulfasalazine is relatively ineffective outside of this subtype. A more recent study of sulfasalazine in patients with systemic JRA demonstrated that side effects lead to the discontinuation of therapy in three out of four patients. 41 It is thought that these side effects were due to a hypersensitivity reaction to sulfasalazine. Even with numerous side effects, it is one of the faster-acting disease-modifying drugs, with benefits seen as short as two months into therapy.6,30 Therapy with sulfasalazine should be initiated at 10 mglkg/day and increased weekly at the same increment until a dose of 50--60 mglkg/day is reached. 2 ,6 The medication is divided into four doses and should be taken with food to decrease gastrointestinal irritation. 6 Once efficacy is established, the dose can be decreased, at which point the average dose needed to maintain response is 25 mg/kg/day.6 A trial of 3 months is recommended to determine the full effectiveness of the drug. 2 Monitoring parameters include periodic complete blood counts and chemistry panels. 6
Methotrexate Methotrexate (MTX) has become increasingly important in the treatment of JRA, and while classified as an immunosuppressive agent, for purposes of discussion it will be addressed separately from the other immunosuppressive agents. 7 The mechanism of action of MTX is complex and involves the inhibition of dihydrofolate reductase. 27 Methotrexate also inhibits the local and systemic inflammatory effects of interleukin-l.2,27 Other mechanisms of action involving folate-dependent pathways have been proposed. 2 ,27 The disease-modifying effect of the drug has been well demonstrated in radiologic studies. One study was done in 23 pediatric patients who had progressing rheumatoid arthritis as evidenced through radiologic imaging. 43 Results ofthe study showed that 17 patients responded to therapy at doses of 7.5 to 10 mg/m 2 /wk, and 11 of those patients showed improved length of the carpal bone in the wrist after a mean duration of therapy of 2.5 years.
Methotrexate should be initiated at 10 mg/m 2 once a week to be given on an empty stomach, approximately 60 minutes prior to the first mea1. 6 For ease of dosing, the injectable preparation has been used orally. 6 In those patients with unresponsive disease, a higher dose may be used. Side effects of MTX include headache, stomatitis, gastrointestinal ulceration with subsequent hemorrhage, diarrhea, abdominal pain, liver enzyme abnormalities, alopecia, interstitial pneumonitis, hepatic cirrhosis, and bone marrow suppression.2.6.27JO The latter four adverse effects are relatively rare. Therapy should be monitored with baseline CBC including mean cell volume and transaminase levels every week for 3 weeks, then twice a week for 2 weeks, then monthlyY
Numerous trials have been done over the past few years with MTX as treatment for JRA. Initial studies were aimed at assessing the safety and efficacy of MTX in pediatric populations with rheumatoid arthritis. A prospective study involving 23 children did just that. 44 Doses ranging from 0.11-0.6 mglkg/week were gi ven over a period of 0.5 to 4.3 years. Methotrexate serum concentrations were obtained at one hour post ingestion. The results showed that 21 of the children had significant improvement, two of whom went into remission. Remission occurred at an average of three months. The only side effect observed was elevated liver transaminase levels that occurred in three patients with systemic onset JRA and prompted discontinuation of therapy. When the liver function tests normalized, therapy was reinstituted. There was no evidence of decreased MTX clearance which could have potentiated toxicity. It was concluded that a dose of 0.3 mglkg/week and one hour post dose serum levels of approximately 5.8 x 10-7 M may be needed to produce a beneficial effect. Another study was initiated to test the efficacy of low dose MTX in systemic onset JRA. 45 The population consisted of 12 patients who were taking approximately 8.5 mg/m 2 /week. The results after 6 months showed a beneficial response in one-third of the patients. Side effects included one case each of elevated transaminase levels, mouth ulcers, and gastrointestinal problems. All of these side effects disappeared upon reduction ofdose or discontinuation of therapy. A joint trial between the U.S. and U.S.S.R. evaluated 127 JRA patients who were given MTX for greater than 6 months. 46 These patients were divided into therapy groups of low dose MTX (10 mg/m 2 /week), very low dose MTX (5 mg/m 2 /week), and placebo. Results indicated that the low dose group experienced more significant effectiveness than either of the remaining two groups. Side effects caused only three patients to stop treatment.
Treatment according to JRA subtype has become an increasingly important part of clinical trials, and there may be a different response rate to MTX depending upon disease subtype. Results of a study in 30 patients with JRA found that response to MTX was considerably less frequent in the systemic onset group of patients than in the polyarticular group, especially those with ANA positivity. 47 The dose ofMTX used for the study was initiated at 0.2-0.3 mglkg/week and then progressively increased, not exceeding 0.8 mglkg/week. This study population demonstrated a greater incidence of side effects than discussed in the other studies.
Many patients with JRA may become resistant to traditional therapeutic approaches. One study investigated high dose MTX in 21 patients with refractory JRA. 48 The participants in the study received an average of 27 mglkg/week. The results of the study after 15 months showed that only 33% responded, with one patient reaching remission. Radiologic evidence showed that most patients had progression of the disease. Side effects included nausea, vomiting, abdominal discomfort, anorexia, and elevation of transaminases. These side effects were not significant enough to cause withdrawal of any of the patients. Conclusions drawn from this study indicate that high doses of MTX can be tolerated, however, the benefit observed may be lower than seen in previous studies with low dose MTX.
Long-term efficacy is always important in treatmeflt of disease states that could potentially be lifelong. Several studies have been done involving the long-term effects of MTX therapy.49-52 The results of these trials have shown that toxicity previously thought to be severe with MTX is not as common as once thought. Periods of time ranging from 6 to 72 months and cumulative doses of greater than 3000 mg or 2300 mg/m 2 are reviewed in vari-ous trials. These trials, although they were small, found no evidence of significant toxic effects. One study in particular investigated the possibility of liver fibrosis. 49 The evidence was . conclusive that although histological changes did occur over time, no significant hepatic damage occurred. Concern has been expressed regarding disease flaring after discontinuation of MTX therapy, and this theory has been the subject of several studies. One of the studies involved a retrospective review of25 patients who were in remission after MTX therapy. 53 The rate of relapse was 52%, and this occurred on average 11 months after therapy was discontinued. After re-treatment, 10 of the patients who had relapsed reached remission again after an average of 7 months of therapy. There were no predictors of which variables might have caused relapses to occur. In a second retrospective study, 17 patients out of 30 total patients entered remission. 54 Of these 17 patients, relapse occurred within 9 months in 5 patients, and greater than 1 year in the remaining 12. Conclusions drawn from the study were that a greater number of pauciarticular patients relapsed sooner and responded less to an additional trial of methotrexate. The authors' state that the data suggest that methotrexate therapy should continue longer after the onset of clinical remission in this subtype.
Recently the FDA approved leflunomide (Arava®), an agent for adult rheumatoid arthritis that is considered to be an alternative to MTX. 55 Leflunomide is a prodrug that is metabolized to the active drug, An 1726, which through the inhibition of de novo pyrimidine synthesis, exerts its anti-inflammitory effect. Several studies ofleflunomide versus comparator agents have shown similar outcomes to methotrexate and sulfasalazine in terms of the American College of Rheumatology (ACR) score (which incorporates joint swelling/tenderness, physician assessment, patient assessment, functional measures, pain, and ESR or C-reactive protein). Leflunomide has a sideeffect profile similar to methotrexate, including hepatic enzyme elevations, diarrhea, alopecia, and rash. For adult patients, it is fairly well accepted that leflunomide is as effective as methotrexate at slowing progression and improving symptoms but remains a second-line agent due to cost and limited experience. There is no published literature at this point on the use of leflunomide in JRA patients, so its role in this population is unknown.
Immunosuppressive Therapy
Immunosuppresive therapy for IRA has been described with cyclosporine, azathioprine, chlorambucil, and cyclophosphamide. 4, 6, 7, 27, 30, 56, 57 Azathioprine, one of the first immunosuppressive drugs used in IRA in the early 1980s, has been studied and shown to be significantly different from placebo. 27 It is not used as frequently in the treatment of IRA since the appearance of MTX in the late 1980s. A follow-up study of 129 patients on azathioprine therapy showed that 38% completed two years with significant improvement, 9 of which attained complete remission. 57 Additional conclusions showed that azathioprine had no effect on iridocyclitis, and side effects were seen in 14% of the patients. The most frequent side effects were gastrointestinal symptoms, increased liver enzymes, and bone marrow suppression. The more severe side effects included four cases of malignancies, 12 patients with secondary amyloidosis, liver necrosis, and several cases of severe systemic infections. In all of these cases, causality could not be established for the side effects seen due to the multitude of concurrent medications including glucocorticoids, chlorambucil, and MTX.
Cyclophosphamide is also not routinely used in the treatment of IRA, however, a small study in severe systemic disease showed a positive response in all patients. 58 The treatment consisted of 6 to 10 monthly intravenous cyclophosphamide infusions of 500-1000 mg/m 2 and methylprednisolone 30 mglkg (maximum of 1 g), with mesna and intravenous fluids as adjunctive therapy. Three of the four patients went into remission after 12 to 20 pulses, and all patients were able to discontinue glucocorticoid therapy. This study opened up the possibility for cyclophosphamide to be used in refractory systemic IRA patients, however, the possible long-term side effects of malignancy and gonadal dysfunction require great consideration before this therapy is implemented.
The use of cyclosporin A in several studies has led to increasing interest in its use as therapy for IRA. The mechanism of action for its therapeutic effect is an inhibition of interleukin-2 transcriptionP Several cases of IRA patients with subsequent development of macrophage activation syndrome were treated effectively with cyclosporin A, 4 The side effects of cyclosporin include increased creatinine, hypertension, renal toxicity, and relatively infrequent bone marrow suppres-
It t ese 10 mm ,however, a recent study seems to suggest that it may be a useful adjunct in severe JRA, 56 The study demonstrated that a mean dose of 3.2 mglkglday (significantly lower than any used in previous trials) in patients with refractory JRA, with or without methotrexate, led to an improvement in symptoms, a significant reduction in steroid dose, and relatively few side effects. Evidence of benefit was seen within 1 to 3 months. The few side effects noted were gastrointestinal and several cases of infection, possibly due to immunosuppression. The authors suggest that cyclosporin be initiated at 2.5-3 mglkglday, and subsequently decreased if the patient's serum creatinine level increases more than 30% from baseline. Additional studies have shown through radiologic analysis that the use of cyclosporin A may decrease the progression of IRA. 56 Future research needs to include larger clinical trials to determine the effectiveness of this drug.
EXPERIMENTAL THERAPY
Many of the experimental drugs in practice have been discovered with a better understanding of the JRA disease process, such as the role of cytokine and other inflammatory media-tors. 8 -10 In addition, the use of newer drugs with proven efficacy and safety in the adult population of rheumatoid arthritis patients has led to an increasing amount of extrapolation of results and subsequent trials in the pediatric population. A discussion follows of several of the agents with limited data available on efficacy in IRA.
Intravenous immunoglobulin has been accepted as an adjunct to therapy in the treatment of various other autoimmune diseases such as dermatomyositis, Kawasaki disease, Guillian-Barre syndrome, and idiopathic thrombocytopenic purpura. 30 • 59 One of the theories of intravenous immunoglobulin (IVIG) therapy in IRA is that IVIG contains antibodies that may disrupt the upregulation of the immune system. This, in tum, may lead to a decreased immune response. 59 Several studies have been published in which trials of IVIG were given to patients with IRA. 5 9-61 One of the studies was a phase 1111 study in 25 patients with polyarticular IRA. 61 The results showed that 19 patients had a clinically significant response after the open phase. Upon randomization to placebo, 5 of the placebo treated patients relapsed within 1.8 to 3.2 months, 4 of which were retreated with IVIG. There were no significant adverse reactions requiring discontinuation of IVIG. Conclusions were that no significant predictor existed as to which patients might be more likely to respond to IVIG, although a slight predominance of efficacy was seen in those patients with the shortest duration of disease before initiation of treatment. Additionally, a combination of IVIG with the study medications (i.e., MTX, prednisone) provided no increased response. After final evaluation ofthe data, it was observed that a significant relapse rate was seen upon discontinuation of IVIG therapy, and although it appears relatively safe with a high percentage of patients who initially responded, the increased cost of therapy and the questionable long-term benefit may preclude widespread use until further clinical trials are done. Due to the lack of results regarding long-term use, a retrospective chart review was performed to determine the effects after the use of IVIG in 27 patients. 59 The results encompassed a length of treatment time ranging from 3 to 54 months. At final follow-up, approximately 50% of the individuals showed some improvement. A trend toward improvement was seen in those patients on concomitant methotrexate, while it was also shown as a steroid-sparing therapy. A discussion of the results showed that a possible predictor of response may lie in the results observed after the first 6 months of therapy. So, while IVIG is a possible therapy in IRA, the results are controversial at best.
Significant research into the role of inflammatory cytokines in IRA has led to implication of tumor necrosis factor (TNF) as a major contributor.8-1O Several biotech drugs with TNF-blocking effects have been approved recently by the FDA. Etanercept (Enbrel®) has been approved for the treatment of signs and symptoms of RA in adults who have not responded adequately to one or more diseasemodifying anti-rheumatic drugs such as methotrexate. 62 Etanercept is a fusion protein consisting of the binding portion of human TNF receptor linked to the Fc portion of the human IgG1 and is produced using recombinant technology. By blocking the activity of TNF, etanercept decreases the effect of TNF on inflammatory cells and many other proteins involved in leukocyte migration and inflammation.
Clinical trials showing efficacy in adults with RA led to the FDA approval of this agent, but some preliminary research has been done in children also. In an open label trial, 69 IRA patients with polyarticular disease aged 4 to 17 years received 0.4 mglkg ofetanercept subcutaneously twice a week for 3 months. Of 54 patients available for evaluation, 76% had improvement as defined by the IRA Defmition of Improvement score (defined as 30% improvement in at least 3 of 6, 30% worsening in no more than I of 6 of the IRA core set of criteria which include physician and patient global assessments, active joint count, limitation of motion, functional assessment, and ESR.) Although the trial was small, the drug seemed to be safe in children, however, the incidence of abdominal pain and vomiting was much higher than in adults, and two patients who had active varicella while on etanercept appeared to develop viral meningitis symptoms. Although the patients recovered without sequelae, the investigators recommended having pediatric patients up to date on their immunizations prior to initiating etanercept, since the effect on the immune system is not yet fully understood. These very promising data will likely lead to more research in JRA.
Similar to etanercept, infliximab (Remicadeĩ s an anti-TNF agent that is under investigation for its potential utility in JRA. 6 3 Infliximab differs from etanercept in that it is an anti-TNF antibody that directly inactivates TNF. There are a few case reports and controlled studies that have been published regarding infliximab use in RA, however, no studies have been published to date using infliximab in the JRA population.
MISCELLANEOUS THERAPIES
A recent study into the etiology of rheumatoid arthritis found an inflammatory reaction after T-cell sensitization. Subsequently, a trial of oral type II collagen was performed in animal models with some success, then in an adult population with rheumatoid arthritis. The proposed mechanism for the treatment is that a protein which is ingested will react with the immune system in the gastrointestinal tract and in tum cause a total systemic immunity. Recently, a pilot trial of oral type II collagen given for 3 months was done in a population of 10 children. Results showed a favorable response in several of the children, with one attaining remission. No significant adverse reactions were noted. This study has demonstrated the need for further clinical trials with this agent. 64 Gamma interferon has been the subject of research as a new therapy in JRA. 10 Many mechanisms of action have been theorized and studied. Findings in an adult population with rheumatoid arthritis have shown that gamma interferon is diminished by leukocytes in vitro. 65 Additional research has shown the effec-tiveness over time with gamma interferon in the treatment of adult RA when dosage decreases are made. Due to this finding, a placebocontrolled double-blind study with gamma interferon in adults with rheumatoid arthritis was undertaken. 65 The results of the study showed a 58% response to the treatment. Since then, gamma interferon has been studied as a pilot trial in 9 pediatric patients with systemic onset JRA. 65 The dose given was 0.5 mcglkglday subcutaneously every day for the first three weeks. The next three weeks the dose was the same but was administered 3 times a week. Afterwards, the dose was decreased according to patient response and gi ven once or twice a week. The duration of therapy was 3 to 39 weeks. Seven of the nine patients enrolled in the study experienced improvement as early as the first few weeks of treatment, and two patients withdrew. One patient withdrew from the study after the disease activity worsened, and the other patient dropped out due to a local reaction at the site of injection. Overall, a clinically significant decrease in the C-reactive protein levels and erythrocyte sedimentation rate was seen. In addition, the hemoglobin was found to have increased after treatment. Controversy still exists over whether or not it is an effective drug for rheumatoid arthritis. Studies in the future may help determine its place in therapy for patients with JRA.
THE FUTURE OF JRA
The future of JRA is looking brighter because of better diagnostic aids, increasing research into the etiology of JRA, and new products on the horizon. Unfortunately, much ofthe information and drug therapy used is extrapolated from studies performed in adults with rheumatic disorders, and there is an increasing awareness that the results may not be as applicable as was once believed.
CONCLUSION
Juvenile rheumatoid arthritis, while not an overly common disorder of childhood, can be-come an extremely debilitating disorder if not diagnosed and treated appropriately. Many of the therapeutic agents first used to treat JRA are still in use today. In addition, several second-line agents such as methotrexate are moving toward the forefront of treatment. Improved blinded, randomized, placebo-controlled studies are being sought to help determine the relative efficacy and long-term safety of the newer agents available today. Until all the facts are in regarding efficacy, safety, and cost-effectiveness, treatment is still based upon trial and error, and therapy is extremely individualized. It is important for pharmacists to realize that the treatment of a disease such as JRA must be approached as a healthcare team model. Their role in the healthcare team is to help educate and provide encouragement and support to increase adherence to the therapy of the patient. both physical and pharmacological. Lastly, they must become drug experts in the evaluation and application of literature to the patient population with this disease.
